International Journal of Molecular Medical Science, 2025, Vol.15, No.5, 205-213 http://medscipublisher.com/index.php/ijmms 213 Leuzy A., Mattsson-Carlgren N., Palmqvist S., Janelidze S., Dage J., and Hansson O., 2021, Blood‐based biomarkers for Alzheimer's disease, EMBO Molecular Medicine, 14(1): e14408. https://doi.org/10.15252/emmm.202114408 Márquez F., and Yassa M., 2019, Neuroimaging biomarkers for Alzheimer’s disease, Molecular Neurodegeneration, 14(1): 21. https://doi.org/10.1186/s13024-019-0325-5 McGrowder D., Miller F., Vaz K., Nwokocha C., Wilson-Clarke C., Anderson-Cross M., Brown J., Anderson-Jackson L., Williams L., Latore L., Thompson R., and Alexander-Lindo R., 2021, Cerebrospinal fluid biomarkers of Alzheimer’s disease: current evidence and future perspectives, Brain Sciences, 11(2): 215. https://doi.org/10.3390/brainsci11020215 Ossenkoppele R., Kant R., and Hansson O., 2022, Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials, The Lancet Neurology, 21: 726-734. https://doi.org/10.1016/s1474-4422(22)00168-5 Papaliagkas V., Kalinderi K., Vareltzis P., Moraitou D., Papamitsou T., and Chatzidimitriou M., 2023, CSF biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer’s disease, International Journal of Molecular Sciences, 24(10): 8976. https://doi.org/10.3390/ijms24108976 Petracci I., Bellini S., Goljanek-Whysall K., Quinlan L., Fiszer A., Cakmak A., Njume C., Borroni B., and Ghidoni R., 2025, Exploring the role of micrornas as blood biomarkers in Alzheimer’s disease and frontotemporal dementia, International Journal of Molecular Sciences, 26(7): 3399. https://doi.org/10.3390/ijms26073399 Siedlecki-Wullich D., Miñano-Molina A., and Rodríguez-Álvarez J., 2021, microRNAs as early biomarkers of Alzheimer’s disease: a synaptic perspective, Cells, 10(1): 113. https://doi.org/10.3390/cells10010113 Smirnov D., Ashton N., Blennow K., Zetterberg H., Simrén J., Lantero-Rodríguez J., Karikari T., Hiniker A., Rissman R., Salmon D., and Galasko D., 2022, Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change, Acta Neuropathologica, 143: 487-503. https://doi.org/10.1007/s00401-022-02408-5 Uchida Y., Nishimaki K., Soldan A., Pettigrew C., Ho S., Moghekar A., Wang M., Miller M., Albert M., and Oishi K., 2025, Change points for dynamic biomarkers in the Alzheimer's disease pathological cascade: a 30‐year cohort study, Alzheimer's and Dementia, 21(8): e70544. https://doi.org/10.1002/alz.70544 Yang Z., Sreenivasan K., Strom E., Osse A., Pasia L., Cosme C., Mugosa M., Chevalier E., Ritter A., Miller J., Cordes D., Cummings J., and Kinney J., 2023, Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease, Alzheimer's Research and Therapy, 15(1): 190. https://doi.org/10.1186/s13195-023-01340-4 Zhang H., Wei W., Zhao M., Ma L., Jiang X., Pei H., and Cao Y., 2021, Interaction between Aβ and Tau in the pathogenesis of Alzheimer's disease, International Journal of Biological Sciences, 17: 2181-2192. https://doi.org/10.7150/ijbs.57078 Zu L., Wang X., Liu P., Xie J., Zhang X., Liu W., Li Z., Zhang S., Li K., Giannetti A., Bi W., Chiavaioli F., Shi L., and Guo T., 2024, Ultrasensitive and multiple biomarker discrimination for Alzheimer's disease via plasmonic and microfluidic sensing technologies, Advanced Science, 11(24): 2308783. https://doi.org/10.1002/advs.202308783
RkJQdWJsaXNoZXIy MjQ4ODYzNA==